Access Not Denied
Any diagnostics, treatments and vaccines developed to combat COVID-19 must be suitable for use in all countries, including resource-poor settings
Stephanie Sutton |
COVID-19’s devastating impact on wealthy countries, such as Italy, Spain, the UK, and the US, has been well publicized. These countries have modern healthcare systems and significant resources, and yet have still struggled to contain the virus and protect their populations. But what about low-to-middle-income countries, where access to even essential medicines can be difficult? Latin America has recently emerged as the new COVID-19 epicenter – and has far less resources than western Europe to deal with the situation. In Africa, up to 190 000 people could die of COVID-19 in the first year of the pandemic if containment measures fail, according to the World Health Organization (1). Other low-to-middle-income regions are also facing the oncoming wave.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.